Case Report: Longitudinal Extensive Transverse Myelitis With Novel Autoantibodies Following Two Rounds of Pembrolizumab

Case Report: Longitudinal Extensive Transverse Myelitis With Novel Autoantibodies Following Two Rounds of Pembrolizumab

A 63-year-old male with metastatic non-small cell lung cancer developed longitudinal extensive transverse myelitis (LETM) following two cycles of Pembrolizumab, an immune checkpoint inhibitor (ICI) targeting the programmed cell death receptor 1 (PD-1). Magnetic resonance imaging (MRI) showed centrom...

Full description

Bibliographic Details
Main Authors: Salma Charabi, Lotte Engell-Noerregaard, Anna Christine Nilsson, Christian Stenör
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-04-01
Series:Frontiers in Neurology
Subjects:
immune checkpoint inhibitors
transverse myelitis
immune related adverse events
pembrolizumab
case report (source: MeSH NLM)
neurological immune-related adverse effects
Online Access:https://www.frontiersin.org/articles/10.3389/fneur.2021.655283/full

Internet

https://www.frontiersin.org/articles/10.3389/fneur.2021.655283/full

Similar Items